Effects of a Novel Dual Phosphodiesterase 3 and 4 Inhibitor TQC3721 in Patients With COPD in China (PACER-II): A Phase 2, Multicenter, Randomized, Double-Anonymized, Placebo-Controlled Trial

Journal:
Chest
Published:
DOI:
10.1016/j.chest.2025.12.055
Affiliations:
25
Authors:
24
Go to article
Institutions Authors Share
West China School of Medicine/West China Hospital of Sichuan University (WCSM/WCH), SCU, China
3.800000
 0.16
Chia Tai Tianqing Pharmaceutical Group Co. Ltd., China
2.500000
 0.10
Suining Central Hospital, China
2.000000
 0.08
Yixing People’s Hospital, JSU, China
2.000000
 0.08
Jiangxi Provincial People's Hospital, China
1.000000
 0.04
Puyang Oil Field General Hospital, China
1.000000
 0.04
Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, China
1.000000
 0.04
The First People's Hospital of Shangqiu, China
1.000000
 0.04
Heze Municipal Hospital, China
1.000000
 0.04
Northern Jiangsu People's Hospital, China
1.000000
 0.04
Siping Central People's Hospital, China
1.000000
 0.04
Ruijin Hospital, SJTU, China
1.000000
 0.04
First Affiliated Hospital, SHZU, China
1.000000
 0.04
Chifeng Municipal Hospital, China
1.000000
 0.04
Zunyi Medical University (ZMU), China
1.000000
 0.04
The General Hospital, TMU, China
1.000000
 0.04
First Hospital of Lanzhou University, LZU, China
1.000000
 0.04
Nanjing Medical University (NJMU), China
0.500000
 0.02
State Key Laboratory of Respiratory Health and Multimorbidity, China
0.200000
 0.01